CSV April 28, 2023 through April 28, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROPIVACAINE	*USP Reference*	*USP43–NF38*	3945	29-May-2020	1-Jun-2020	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE INJECTION	*standards <11>*							Ropivacaine Related Compound A RS: Change 2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND In USP Ropivacaine Related Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89 to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R)-N*-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DOXYCYCLINE CAPSULES	PERFORMANCE TESTS	*USP43–NF38*	1519	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Dissolution <711>*: Change *Test 2* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.
DOLASETRON MESYLATE	ASSAY/ *Procedure*	*USP43–NF38*	1483	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *Mobile phase*: Acetonitrile, water, and 1 M ammonium formate (450:440:110), adding 0.19 mL of triethylamine to the acetonitrile portion to: *Solution A*: Add 0.19 mL of triethylamine to each 450 mL of acetonitrile. *Mobile phase*: *Solution A*, water, and 1 M ammonium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								formate (450:440:110)
INDOMETHACIN SUPPOSITORIES	ASSAY/ *Procedure*	*Revision Bulletin (Official December 01, 2019)*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Chromatographic system/ Detector*: Change PDA (scan 200–600). to: PDA (scan 200–600 nm).
CARISOPRODOL	IMPURITIES/*Organic Impurities*	*USP43–NF38*	776	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Table 2*: Change Carisoprdol related compound A[a] to: Carisoprodol related compound A[a]
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5419	24-Apr-2020	1-May-2020	*NA*	*NA*	In the variable definition for *F* in *Vitamin E, Method 2/Analysis*: Change 1/2 for products labeled to contain *all-rac*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								vitamin E sources) to: 1/2 (for products labeled to contain *all-rac* vitamin E sources) AND In *Biotin, Method 2/Basal medium stock solution*: Change Dissolve the anhydrous dextrose and anhydrous Sodium acetate to: Dissolve the anhydrous dextrose and anhydrous sodium acetate AND In *Cyanocobalamin, Method 2/Basal medium*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								stock solution: Change thedextros, to: the dextrose, AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Thiamine, Method 3/Analysis: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid ($C_6H_8O_6$)
DIHYDROERGOTAMINE MESYLATE	*Assay*	*USP43–NF38*	1388	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Diluent 1*—Prepare a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution of 0.1 mL of phosphoric acid in 1000 mL of water. *Diluent 2*—Prepare a mixture of *Diluent 1* and acetonitrile (60:40). to: *Diluent 1*—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL of water.
GLYCERYL MONO AND DICAPRYLATE	IDENTIFICATION/*A. Fatty Acid Composition*	*USP43–NF38*	5794	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Standard solution 3*: Change USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Laurate RS. to: USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl Myristate RS.
LEVONORDEFRIN	*Identification/B:*	*USP43–NF38*	2611	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption <197U>—* to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
0.002 M EDETATE DISODIUM VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.0744 g to: 0.744 g
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENT	*USP43–NF38*	3388	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Pantoprazole

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S/*USP Reference Standards <11>*							Related Compound E RS: Change $C_{34}H_{28}F_4N_6O_8S_2$ 764.74 to: $C_{32}H_{28}F_4N_6O_8S_2$ 764.72
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>/Test 2*	*Revision Bulletin (Official October 01, 2019)*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Buffer stage medium*: Change Simulated gastric fluid, to: Simulated intestinal fluid,
RALTEGRAVIR TABLETS	ASSAY/*Procedure*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
RALTEGRAVIR CHEWABLE TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	915	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 506.98 to: 506.97
OIL-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Vitamin E, Method 3*/*Analysis*: Change alpha -ocopheryl acetate to: alpha-tocopheryl acetate
DEMECLOCYCLINE HYDROCHLORIDE	SPECIFIC TESTS/*Loss on Drying*	*USP43–NF38*	1248	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change Dry the *Sample* at 60° for 3 h. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5552	24-Apr-2020	1-May-2020	*NA*	*NA*	Dry the *Sample* in a capillary-stoppered bottle in vacuum at 60° for 3 h. In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EPINEPHRINE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	*Method 3*/*Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4*/*Analysis*: Add ascorbic acid ($C_6H_8O_6$), This erratum applies to the USP-NF ONLINE

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								platform only. In *USP Reference Standards* <*11*>: Add USP Racepinephrine Hydrochloride RS
SODIUM META BISULFITE	IM PURITIES/*Limit of Chloride*	*USP43–NF38*	6020	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change (see *Nephelometry, Turbidimetry, and Visual Comparison* <855>). to: (see *Visual Comparison* <630>).
MEXILETINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP43–NF38*	2943	24-Apr-2020	1-May-2020	*NA*	*NA*	Change [5370-01-04]. to: [5370-01-4].
NEAR-INFRARED SPECTROSCOPY	4. VALIDATION AND VERIFICATION	*USP43–NF38*	7161	24-Apr-2020	1-May-2020	*NA*	*NA*	In *4.1 Validation/4.1.1 Accuracy/Validation criteria/Criteria 1*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Suitable agreement between SEP to: Suitable agreement between the standard error of prediction (SEP)
PROPRANOLOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3746	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Relative standard deviation*: Change NMT 5.0, to: NMT 5.0%,
RALTEGRAVIR CHEWABLE TABLETS	ASSAY/*Procedure*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_1= molecular weight of raltegravir, 444.42
VITAMIN E	ASSAY/*Alpha Tocopheryl Acid Succinate*	*USP43–NF38*	4637	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Sample solution*: Change tocoopheryl to: tocopheryl
REPOSITORY CORTICOTROPIN INJECTIONS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	1174	24-Apr-2020	1-May-2020	*NA*	*NA*	In *USP Reference Standards <11>*: Add USP Ascorbic Acid RS
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5476	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add ascorbic acid ($C_6H_8O_6$), AND In *Molybdenum, Method 2/Instrumental conditions*: Change (See *Atomic Absorption Spectroscopy <852>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
EPINEPHRINE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	1645	24-Apr-2020	1-May-2020	*NA*	*NA*	In the third calculation in the *Analysis*: Change C_U = concentration of Epinephrine in the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL) to: C_U = concentration of Epinephrine in the *Sample solution* (µg/mL)
HEXYLENE GLYCOL	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	5814	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Any other individual impurity/Relative Response Factor* in *Table 2*: Change – to: 1.0
LOPERAMIDE HYDROCHLORIDE	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	2658	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Peak-to-valley ratio*: Change NLT 1.5 for loperamide related compounds G and H; NLT 1.5 for loperamide related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compounds E and A, *System suitability solution* to: NLT 1.5 for loperamide *cis*-*N*-oxide and an hydroloperamide; NLT 1.5 for loperamide piperidinolamide and loperamide biphenyl analog, *System suitability solution*
0.02 M EDETATE DISODIUM VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.7444 g to: 7.444 g
POLYVINYL ALCOHOL	IDENTIFICATION/*A.*	*USP43–NF38*	3593	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Infrared Absorption* <197K> to: *Spectroscopic Identification Tests* <197>, *Infrared*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Spectroscopy: 197K
RALTEGRAVIR TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
SACCHARIN SODIUM	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USP43–NF38*	3965	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Matching fluid A*: Change ferric chloride TS, to: ferric chloride CS,
BUDESONIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	604	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote k in *Table 2*: Change 16?,17-[Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione-21-acetate. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								16?,17-[Butylidenebis(oxy)]-11?-hydroxypregna-1,4-diene-3,20-dione-21-yl acetate.
OIL-SOLUBLE VITAMINS TABLETS	ADDITIONAL REQUIREMENTS/*Labeling*	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote 1: Change -alpha-tocopheryl to: *all-rac*-alpha-tocopheryl AND Change USP Vitamin E unit to: USP Vitamin E Unit AND Change 2*R* -alphatocopherol to: 2*R*-alpha-tocopherol
DEXAMETHASONE ACETATE	*Chromatographic purity*	*USP43–NF38*	1290	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Format buffer* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPRYLIC ACID	ASSAY/*Procedure/Chromatographic system*	*USP43–NF38*	5664	24-Apr-2020	1-May-2020	*NA*	*NA*	*Formate buffer* In *Column*: Change 30-cm to: 30-m
LEUCOVORIN CALCIUM FOR INJECTION	ASSAY/*Procedure/Chromatographic system*	*USP43–NF38*	2569	24-Apr-2020	1-May-2020	*NA*	*NA*	Delete *Run time*: 2 times the retention time of the leucovorin peak
SUCROSE PALMITATE	IMPURITIES/*Inorganic Impurities*	*USP43–NF38*	6078	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Fats and Fixed Oils, Acid Value <401>*: Change NMT 6.0%, to: NMT 6.0,
NIACIN	IDENTIFICATION/*B.*	*USP43–NF38*	3138	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NUCLEIC ACID-BASED TECHNIQUES -- GENERAL	APPENDICES	*USP43–NF38*	7865	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Appendix 2*: Delete the Row for dNTP dinucleotide triphosphate
RALTEGRAVIR TABLETS	DEFINITION	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	Change ($C_{20}H_{20}FN_6O_5$) to: ($C_{20}H_{21}FN_6O_5$)
RALTEGRAVIR CHEWABLE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
ALOSETRON HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	141	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/ *Resolution*: Change NLT 7 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM AND VITAMIN D WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	4845	24-Apr-2020	1-May-2020	*NA*	*NA*	NLT 3 In *Calcium, Copper, Magnesium, Manganese, and Zinc, Method 2/Acceptance criteria*: Change NLT 90.0%–125.0% to: 90.0%–125.0%
DAPSONE TABLETS	IDENTIFICATION/*B.*	*USP43–NF38*	1241	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5512	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Biotin, Method 3/Solid-phase extraction*: Change anion-xchange

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: anion-exchange AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EPINEPHRINE	IM PURITIES/ *Enantiomeric Purity*	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid ($C_6H_8O_6$), This erratum applies to the USP-NF ONLINE platform only. In *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability solution: Change 0.03 mg/mL of in *Mobile phase* to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in *Mobile phase*
POLYOXYL 35 CASTOR OIL	IDENTIFICATION/*C. Identity by Fatty Acid Composition*	*USP43–NF38*	5956	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Relative standard deviation*: Change linoeate to: linoleate

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 9
- Page 10
- Page 11
- Page 12

- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- …
- Next page Next ›
- Last page Last »